deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-04 and is reviewed periodically as new material appears.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.
Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.
This is a list of investigational panic disorder drugs, or drugs that are currently under development for clinical use for the treatment of panic disorder (PD) but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]". This list was last comprehensively updated in September 2025. It is likely to become outdated with time.
The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even kidney failure; this can be avoided by using sirolimus instead. It is particularly advantageous in patients with kidney transplants for hemolytic–uremic syndrome, as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on 7 October 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use. In 2009, the FDA notified healthcare professionals that a clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus. A 2019 cohort study of nearly 10,000 lung transplant recipients in the US demonstrated significantly improved long-term survival using sirolimus + tacrolimus instead of mycophenolate mofetil + tacrolimus for immunosuppressive therapy starting at one year after transplant. Sirolimus can also be used either alone or in conjunction with a calcineurin inhibitor (such as tacrolimus) or mycophenolate mofetil, or both, to provide steroid-free immunosuppression regimens.
On March 2, 2026, Hegseth stated that joint U.S.-Israeli military operations against Iran were a response to prolonged Iranian targeting of American interests. He characterized the actions as an effort to conclude an existing conflict, stating, "We didn't start this war but under President Trump we're finishing it." He noted the death of Supreme Leader Ali Khamenei during the strikes, remarking, "This is not a so-called regime change war, but the regime sure did change". He stated that the primary goals were to "destroy the missile threats, destroy the navy," and ensure there are "no nukes". During the briefing, he issued a direct warning to adversaries: "If you kill or threaten Americans anywhere in the world... we will hunt you down, and we will kill you". Hegseth stated on March 4, 2026, that the Pentagon was "investigating" reports of a deadly airstrike on the Shajareh Tayyebeh girls' school in Minab, Iran, while maintaining that the U.S. military "never targets civilian sites." Evidence indicated that it was the U.S. which most likely bombed the school. On March 10, 2026, Hegseth accused Iran of firing missiles from schools and hospitals and endangering civilians. He also said that Iran is "badly losing" on day 10 of the war.
== Medical career == In 1955 he joined the IDF and graduated an Artillery officers training course. He then began his academic studies at the Hadassah school of Medicine in Jerusalem. After his graduation he started Orthopedics under Dr Ernst Spira and was posted as a military doctor in the 52nd brigade of the Armored Corps. In 1965 he moved to New York to specialize in Orthopaedic Surgery at the Mount Sinai School of Medicine and the Albert Einstein College of Medicine under Professor Arthur Helfet. At the end of his training he studied Artificial Hip Joint replacement under Professor Philip Wilson II at the Cornell University Hospital for Special Surgery. He then moved to the Lenox Hill Hospital where he established the Hip Surgery clinic with Dr James Nicholas. During his time in New York, he lectured at Albert Einstein, Mount Sinai, Elmhurst and the Brooklyn Children’s hospitals. During the wars in Israel, Six Days War (1967) and Yom Kippur War (1973) he volunteered as a surgeon in the IDF Medical corps. In 1975 he returned to Israel to take up the position of Head of the Orthopaedic Surgery at Bnai Zion Hospital in Haifa. Mendes ran the department of Orthopaedic Surgery until his retirement in 2002. His department offered a variety of innovative surgical procedures to patients from the entire country. Care was given to elderly, adults and infants for Orthopedic diseases benign and malignant and for injuries ranging from sports accidents to war casualties including rehabilitation of amputees.
Sources: en.wikipedia.org
Trump, long known before he took elective office for labeling his companies' properties and merchandise with his name or image, has controversially continued the practice in public life in his second presidential term, in some cases by altering existing names or images. Soon after the term began, Trump's portrait appeared on large banners hung from three federal buildings in Washington, D.C.; U.S. Sen. Adam Schiff (D.-Calif.) objected that the banners violated “a longstanding legal prohibition against the use of federal funds for propaganda and self-aggrandizement purposes.” Trump also promptly dismissed the Kennedy Center's board of trustees, then selected a replacement board, which voted in December to rename the center the Donald J. Trump and the John F. Kennedy Memorial Center for the Performing Arts; its signage was altered to reflect the new name. The change drew criticism from politicians in Congress, some of them in Trump's own party; House minority leader Hakeem Jeffries (D-N.Y.) declared that the board had “no authority to actually rename the Kennedy Center in the absence of legislative action,” and a federal judge later ordered that Trump's name be removed. The new board had appointed Trump himself to its chairmanship, a first for a president. That month, Trump also set his name on the U.S. Institute of Peace (USIP), renaming it the Donald J. Trump Institute of Peace, and its signage, too, was so altered. Trump had recently fired not only the USIP's board but its every employee, turning control of its headquarters over to the General Services Administration.
A blood culture is a medical laboratory test used to detect bacteria or fungi in a person's blood. Under normal conditions, the blood does not contain microorganisms: their presence can indicate a bloodstream infection such as bacteremia or fungemia, which in severe cases may result in sepsis. By culturing the blood, microbes can be identified and tested for resistance to antimicrobial drugs, which allows clinicians to provide an effective treatment. To perform the test, blood is drawn into bottles containing a liquid formula that enhances microbial growth, called a culture medium. Usually, two containers are collected during one draw, one of which is designed for aerobic organisms that require oxygen, and one of which is for anaerobic organisms, that do not. These two containers are referred to as a set of blood cultures. Two sets of blood cultures are sometimes collected from two different blood draw sites. If an organism only appears in one of the two sets, it is more likely to represent contamination with skin flora than a true bloodstream infection. False negative results can occur if the sample is collected after the person has received antimicrobial drugs or if the bottles are not filled with the recommended amount of blood. Some organisms do not grow well in blood cultures and require special techniques for detection. The containers are placed in an incubator for several days to allow the organisms to multiply.
=== FastGC === Gas chromatography (GC) in combination with mass spectrometry (GC-MS) is capable of separating isomeric compounds. Although GC has been successfully coupled to PTR-MS in the past, this approach annihilates the real-time capability of the PTR-MS technology, because a single GC analysis run typically takes between 30 min and 1 h. Thus, state-of-the-art GC add-ons for PTR-MS are based on fastGC technology. Materic et al. utilized an early version of a commercially available fastGC addon in order to distinguish various monoterpene isomers. Within a fastGC run of about 70 s they were able to separate and identify: alpha-pinene, beta-pinene, camphene, myrcene, 3-carene and limonene in a standard mixture, Norway spruce, Scots pine and black pine samples, respectively. Particularly, if the operation mode of a PTR-MS instrument equipped with fastGC is continuously switched between fastGC and direct injection (dependent on the application, e.g. a loop sequence of one fastGC run followed by 10 min of direct injection measurement), real-time capability is preserved, while at the same time valuable information on substance identification and isomer separation is acquired.
The merger was prohibited by the European Commission on the grounds that both Tetra Pak and Sidel were market leaders in their fields and operated in related business areas. The European Court of Justice eventually ruled in favour for Tetra Laval in a high-profile case. The Tetra Laval Group is controlled by the holding company Tetra Laval International, whose board of directors include the three children of Gad Rausing. In 2014, Tetra Pak acquired Miteco, a provider of production solutions for soft drinks, fruit juices and liquid food, which employs 70 people across sites in Switzerland, Italy, the UK and South America.
=== Alternative protein sources === With the global population expected to reach 9.7 billion by 2050, there is an urgent need for alternative protein sources that are sustainable, nutritious, and environmentally friendly. Plant-based proteins are gaining popularity as they require fewer resources and produce fewer greenhouse gas emissions compared to animal-based proteins. Companies like Beyond Meat and Impossible Foods have developed plant-based meat alternatives that mimic the taste and texture of traditional meat products.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.